Home Home Home Inbox Home Search

Event

Long-term Safety and Efficacy of Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis Homozygous for F508del-CFTR or Heterozygous for F508del and a Residual Function Mutation: First Interim Analysis Results of a Phase 3, Open-label, Rollover Study [Board No. 625]

Location: Board no. 625
Session Type: RAPiD: Rapid Abstract Poster Discussion Session
Wednesday
May
23
9:15 AM
11:15 AM

Speaker(s)/Author(s)

Claire L. Keating

MD
Columbia University Medical Center

Manu Jain

MD
Northwestern University;Northwestern University Feinberg School of Medicine

Zheng (Jason) Yuan

PhD, MS
Vertex Pharmaceuticals Incrporated

Lisi Wang

MD, MSc
Vertex Pharmaceuticals Incrporated

Julie Lekstrom-Himes

MD
Vertex Pharmaceuticals Incrporated

Caroline A. Owen

MD, PhD
Vertex Pharmaceuticals Incrporated

Patrick A. Flume

MD
Med Univ of S Carolina;Medical University of South Carolina

Cynthia D. Brown

MS, MD
Indiana University School of Medicine

View Abstract

Long-term Safety and Efficacy of Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis Homozygous for F508del-CFTR or Heterozygous for F508del and a Residual Function Mutation: First Interim Analysis Results of a Phase 3, Open-label, Rollover .

Parent Sessions

  • D23 - ADULT CF AND NON-CF BRONCHIECTASIS...
    05-23-2018 9:15 AM - 11:15 AM
    • Home Home Home Inbox Home Search